ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of CLE in Vivo Diagnosis and ex Vivo Examination Against Surgical Histopathology of CPL (INDEX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02516488
Recruitment Status : Recruiting
First Posted : August 6, 2015
Last Update Posted : April 3, 2018
Sponsor:
Information provided by (Responsible Party):
Somashekar Krishna, The Ohio State University

Brief Summary:
Comparison of confocal laser endomicroscopic in vivo diagnosis and ex vivo examination against surgical histopathology of cystic pancreatic lesions.

Condition or disease
Cystic Pancreatic Disorders

Detailed Description:
The primary objective of the study is to assess the ability of nCLE (AQ-Flex) to accurately diagnose the type of CPL by comparing in vivo and ex vivo CLE patterns to final histopathology of surgically resected CPLs. The primary endpoints are whether or not the CLE diagnosis correlates with final diagnosis (yes vs. no).

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Comparison of Confocal Laser Endomicroscopic IN Vivo Diagnosis and EX Vivo Examination (INDEX Study) Against Surgical Histopathology of Cystic Pancreatic Lesions
Study Start Date : May 2015
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : December 2018



Primary Outcome Measures :
  1. Diagnosis of cystic pancreatic lesion (CPL) using nCLE (confocal laser endomicroscopy) [ Time Frame: 12 months ]
    Comparing the ability of nCLE to accurately diagnose the type of CPL by comparing in vivo and ex vivo CLE patterns to final histopathology of surgically resected CPLs.


Secondary Outcome Measures :
  1. Detection of high-grade dysplasia and/or adenocarcinoma by CLE imaging [ Time Frame: 12 months ]
  2. CLE imaging interpretation variation [ Time Frame: 12 months ]
    Calculate inter-observer variation in CLE image interpretation


Biospecimen Retention:   None Retained
Fluid from cyst in pancreas


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with Cystic Pancreatic Lesions
Criteria

Inclusion Criteria:

For in vivo nCLE (needle-based confocal laser endomicroscopy) (Part 1):

  • Patient age 18 years and older
  • All patients referred for EUS-FNA (endoscopic ultrasound - fine needle aspiration) of accessible CPL (cystic pancreatic lesion)
  • The minimum size of the cyst should be ≥ 1.5 cm as determined by prior cross-sectional imaging studies.

For ex vivo pCLE (probe-based confocal laser endomicroscopy) (Part 2):

  • All patients must satisfy inclusive criteria for in vivo nCLE.
  • All patients should have completed EUS-guided nCLE.
  • All patients should have a CPL lesion referred for surgical removal based on recommended international consensus guidelines1 and inter-departmental consensus pancreatic tumor board meeting (departments of surgical oncology, radiology, pathology and gastroenterology).
  • Patient participated and completed in vivo nCLE (Part 1)

Exclusion Criteria:

  • Unable to obtain informed consent
  • Unable to tolerate the procedure
  • Women with known pregnancy at time of procedure
  • Patient age less than 18 years
  • Bleeding diathesis
  • Lesion not accessible by EUS guided FNA
  • Allergy to fluorescein.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02516488


Contacts
Contact: Casey McClurkin, BS, CCRC 614-688-9575 casey.mcclurkin@osumc.edu
Contact: Alejandra Cervantes, BS 614-685-5418 alejandra.cervantes@osumc.edu

Locations
United States, Ohio
OSU Wexner Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Casey McClurkin, BS, CCRC    614-688-9575    casey.mcclurkin@osumc.edu   
Contact: Alejandra Cervantes, BS    614-685-5814    alejandra.cervantes@osumc.edu   
Principal Investigator: Somashekar Krishna, MD, MPH         
Sponsors and Collaborators
Somashekar Krishna
Investigators
Principal Investigator: Somashekar Krishna, MD, MPH Ohio State Wexner Medical Center